Kaplan Fatih, Topal Erdem
Department of Pediatric Allergy and Immunology, İnönü University Faculty of Medicine, Malatya, Türkiye.
Turk J Pediatr. 2023;65(2):326-329. doi: 10.24953/turkjped.2022.386.
Myasthenia gravis is a chronic, autoimmune disease with muscle weakness. Acetylcholinesterase inhibitors are used in the symptomatic treatment of the disease. Allergic reaction to pyridostigmine bromide is rare. In the literature, no allergic reaction to pyridostigmine bromide has been reported in the pediatric population.
A 12-year-old female patient diagnosed with myasthenia gravis consulted our clinic with the complaint of urticaria due to pyridostigmine bromide. The oral challenge test performed with pyridostigmine bromide was positive. As the patient was required to be continue pyridostigmine bromide with no suitable alternatives, it was decided that the patient had to be desensitized to pyridostigmine. During and after the desensitization protocol, no reaction was observed.
In this report, a successful desensitization protocol for pyridostigmine bromide in a child with myasthenia gravis is discussed.
重症肌无力是一种伴有肌肉无力的慢性自身免疫性疾病。乙酰胆碱酯酶抑制剂用于该疾病的对症治疗。对溴吡斯的明的过敏反应罕见。在文献中，儿科人群中尚未有对溴吡斯的明过敏反应的报道。
一名12岁诊断为重症肌无力的女性患者因溴吡斯的明导致荨麻疹前来我院就诊。用溴吡斯的明进行的口服激发试验呈阳性。由于患者需要继续使用溴吡斯的明且没有合适的替代药物，决定对该患者进行溴吡斯的明脱敏治疗。在脱敏治疗期间及之后，未观察到反应。
在本报告中，讨论了对一名重症肌无力患儿成功进行溴吡斯的明脱敏治疗的方案。
